REMARKS

The Examiner's final Office Action dated October 4, 2006, has been carefully considered. In the present application, claims 1 and 8-18 are pending. Claims 13 and 15-17 are withdrawn from consideration subject to a Restriction Requirement. Claims 1, 8-12, 14 and 18 are objected to. In view of the forgoing amendment and the following remarks, reconsideration and withdrawal of the present basis for objecting to the claims herein of this application is respectfully requested.

I. <u>Discussion of the Amendment</u>

Claim 1, 12 and 18 are amended to the elected and examined subject matter by the Examiner, i.e., limiting R⁰ as substituted isoxazol-3-yl, Q as methylene, and the substituents on the imizazole ring attached as in the Applicants' elected species.

Claims 1, 13, 14, 17 and 18 are also amended to better and more properly reflect what Applicants regard as their invention.

Claims 12-18 are also amended to be dependent upon claim 1.

Claims 8-11 are cancelled, without prejudice.

Applicants reserve the right to pursue the cancelled subject matter in a subsequent application.

This amendment to the claims adds no new matter.

II. <u>Discussion of the Objection to Claims 1, 8-12, 14 and 18</u>

Claims 1, 8-12, 14 and 18 are objected to for allegedly containing non-elected subject matter.

Applicants respectfully submit that claims 1, 12 and 18 have been amended within the scope of allowable subject set forth in the "Status of Claims" section in the Action (see page 3). Furthermore, claims 8-11 have been cancelled, without prejudice. Thus, the instant object is rendered moot by the forging amendment. Accordingly, Applicants respectfully request reconsideration and withdrawal of the instant objection.

Docket No. DEAV2002/0085 US NP Application No.: 10728,339

III. Conclusion

In view of the above remarks, Applicants respectfully submit that the present application is in condition for allowance. Early notice to this effect is, thus, respectfully requested.

If there are any issues that can be resolved by a telephone conference or an Examiner's amendment, the Examiner is invited to call the undersigned attorney at (908) 231-3582.

Respectfully submitted,

Jiang Lin, Registration No. 51,065

Attorney for Applicants

Date: January 4, 2007

sanofi-aventis U.S. LLC Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-3582 Telefax (908) 231-2626

Docket No. DEAV2002-0085 US NP